Collecting and Storing Blood Samples From Patients With Cancer
This study has been withdrawn prior to enrollment.
(Will be replaced by honest broker program)
Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )
ClinicalTrials.gov Identifier:
NCT00900120
First received: May 9, 2009
Last updated: December 8, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting and storing blood samples from patients with cancer.
| Condition |
|---|
|
Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Nonmalignant Neoplasm Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
Sézary syndrome
chronic myeloid leukemia
cytogenetically normal acute myeloid leukemia
essential thrombocythemia
familial acute myeloid leukemia with mutated CEBPA
multiple myeloma
mycosis fungoides
Genetic and Rare Diseases Information Center resources:
Myeloid Leukemia
Acute Myeloid Leukemia
Acute Non Lymphoblastic Leukemia
Myelodysplastic Syndromes
Lymphosarcoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Leukemia, B-cell, Chronic
B-cell Lymphoma
Aplastic Anemia
Chronic Myeloid Leukemia
Myelofibrosis
Hodgkin Lymphoma
Waldenstrom Macroglobulinemia
Acute Lymphoblastic Leukemia
Follicular Lymphoma
Polycythemia Vera
Essential Thrombocythemia
Lymphoma, Large-cell
Chronic Myelomonocytic Leukemia
Burkitt Lymphoma
Childhood Acute Lymphoblastic Leukemia
Anaplastic Large Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Mycosis Fungoides
Hairy Cell Leukemia
Cutaneous T-cell Lymphoma
Lymphoblastic Lymphoma
Chronic Myeloproliferative Disorders
Large Granular Lymphocyte Leukemia
Aggressive NK Cell Leukemia
Leukemia, T-cell, Chronic
Primary Central Nervous System Lymphoma
Sezary Syndrome
AL Amyloidosis
Myelodysplastic/myeloproliferative Disease
Plasmablastic Lymphoma
Lymphoma, Large-cell, Immunoblastic
Juvenile Myelomonocytic Leukemia
Angioimmunoblastic T-cell Lymphoma
Angioimmunoblastic Lymphadenopathy With Dysproteinemia
Adult T-cell Leukemia/lymphoma
Hodgkin Lymphoma, Childhood
Anaplastic Plasmacytoma
Lymphomatoid Granulomatosis
Chronic Neutrophilic Leukemia
U.S. FDA Resources
Further study details as provided by Rutgers, The State University of New Jersey:
Primary Outcome Measures:
- DNA repository for long-term storage of DNA obtained from patients treated at the Cancer Institute of New Jersey [ Time Frame: Indefinite ] [ Designated as safety issue: No ]
- Investigative mechanism to allow correlations between genetic polymorphisms and clinical outcomes [ Time Frame: Indefinite ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood
| Enrollment: | 0 |
| Study Start Date: | March 2004 |
| Study Completion Date: | May 2011 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To establish a repository for long-term storage of DNA obtained from patients treated at the Cancer Institute of New Jersey.
- To establish a mechanism whereby investigators can analyze correlations between genetic polymorphisms and clinical outcomes (e.g., response to treatment).
OUTLINE: Additional blood samples are collected for banking from patients while they are scheduled for routine blood draw as a part of their normal care. Samples are stored in a secure place under the control of the Cancer Institute of New Jersey Tissue Retrieval service. The samples may be used for DNA, RNA, or protein extraction and analyses, as well as generation of cell lines.
Demographic data (ethnicity, race, age, and sex), diagnosis, family history, and previous treatments (chemotherapy, radiation, and surgery) are recorded on the case report form and kept in a secure location in the Office of Human Research Services (OHRS).
Patients may have their samples removed and destroyed at any time.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients seen at CINJ who have a diagnosis of cancer and plan to be treated at CINJ will be asked to participate in this DNA banking resource
Criteria
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed malignancy or bone marrow disorder (i.e., myelodysplasia, myeloproliferative syndrome, or aplastic anemia)
- Must be undergoing treatment or planning to undergo treatment at the Cancer Institute of New Jersey
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900120
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900120
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Kim Hirshfield, MD, PhD | Rutgers Cancer Institute of New Jersey |
More Information
| Responsible Party: | University of Medicine and Dentistry of New Jersey |
| ClinicalTrials.gov Identifier: | NCT00900120 History of Changes |
| Other Study ID Numbers: | CDR0000592848 P30CA072720 CINJ-000402 CINJ-IRB-4856 |
| Study First Received: | May 9, 2009 |
| Last Updated: | December 8, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Rutgers, The State University of New Jersey:
|
aplastic anemia myelodysplastic/myeloproliferative neoplasm, unclassifiable unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific secondary myelodysplastic syndromes accelerated phase chronic myelogenous leukemia acute undifferentiated leukemia adult acute lymphoblastic leukemia in remission adult acute myeloid leukemia in remission adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) atypical chronic myeloid leukemia, BCR-ABL negative |
blastic phase chronic myelogenous leukemia childhood acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood chronic myelogenous leukemia chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia juvenile myelomonocytic leukemia mast cell leukemia meningeal chronic myelogenous leukemia progressive hairy cell leukemia, initial treatment prolymphocytic leukemia recurrent adult acute lymphoblastic leukemia recurrent adult acute myeloid leukemia recurrent adult T-cell leukemia/lymphoma recurrent childhood acute lymphoblastic leukemia |
Additional relevant MeSH terms:
|
Lymphoma Disease Leukemia Syndrome Neoplasms Multiple Myeloma Neoplasms, Plasma Cell Myelodysplastic Syndromes Preleukemia Nervous System Neoplasms Central Nervous System Neoplasms Myeloproliferative Disorders Plasmacytoma Lymphoproliferative Disorders Myelodysplastic-Myeloproliferative Diseases |
Neoplasms by Histologic Type Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Pathologic Processes Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Bone Marrow Diseases Precancerous Conditions Neoplasms by Site |
ClinicalTrials.gov processed this record on September 30, 2016